Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07414836 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
A Phase 1 study, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT07414836: Recruiting Phase 1 study, sponsored by BeOne Medicines.
NCT07414836 is a Phase 1 study that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 84 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07414836, a Phase 1 study, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Safety Expansion) and Phase 1b (Dose Expansion).
Primary Outcome
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including dose limiting toxicities (DLTs), AEs meeting protocol-defined adverse event of clinical interest (AECI) criteria, laboratory values, and electrocardiogram results.
Interventions
- DRUG Tislelizumab
- DRUG BG-C0979
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2026-04-13 |
| Est. Completion | 2029-04-30 |
| Phase | Phase 1 |
What NCT07414836 shows while recruiting
NCT07414836 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% higher).
The record links to 0 conditions, and to 2 interventions - of which Tislelizumab is the first listed.
NCT07414836 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07414836 about?
NCT07414836 is a clinical study titled "A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Safety...
What is the current status of trial NCT07414836?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2026-04-13. Estimated completion is 2029-04-30.
What interventions are being tested in trial NCT07414836?
The interventions under investigation include: Tislelizumab (DRUG), BG-C0979 (DRUG).
Who is sponsoring clinical trial NCT07414836?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07414836's enrollment target sits among peer trials
84 659th of 2000 higher than 1,336 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI